Median Technologies announces launch of a capital increase through a private placement and a public offering

Sophia Antipolis, France

In accordance with the publicity guidelines, press releases referring to the offering were added to Median Technologies’ website regular press release list on Sept. 21, 2023, i.e. more than 40 calendar days following the determination by the CEO acting upon delegation of the board of directors of the Company of the price for the shares to be issued by the Company in the Offering. Press releases referring to the Offering are now available without a special screening mechanism that restricts persons resident in restricted countries from accessing press releases.

Download 20230712_PR_Launch_EN_FV.pdf

About Median Technologies

Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer diagnoses and cancer treatments. Median’s offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. The French-based company, with a presence in the U.S. and China is listed  on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME).

Contacts

Median Technologies
Emmanuelle Leygues
Head of Corporate Marketing and Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Press – ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59
median@alizerp.com

Investors – ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24
ghislaine.gasparetto@seitosei-actifin.com